01
Location:
Homepage
/
/
/
Rituximab has a huge market potential in the field of cancer

Rituximab has a huge market potential in the field of cancer

(Summary description)Text/ChaiYanCancerisamalignantdiseasewhichisseriouslyharmfultohumanhealth.Everyyeararound7millionpeopleintheworlddiefromcancer.Inourcountry,thetumorisonlythehighincidenceofcardiovasculardisease,inurbanresidents,cancerhasbeentheleadingcauseofdeath.Thenumberofnewlydiagnosedcasesofcancereachyear2millionpeople,morethan1million600thousanddeaths,accountingfor18.63%ofthecountry'stotalaverageannualdeathtoll.Atpresent,theincidenceofcancerisstillasignificantupwardtrend,sotheanti-cancerdrughasahugemarket.A

Rituximab has a huge market potential in the field of cancer

(Summary description)Text/ChaiYanCancerisamalignantdiseasewhichisseriouslyharmfultohumanhealth.Everyyeararound7millionpeopleintheworlddiefromcancer.Inourcountry,thetumorisonlythehighincidenceofcardiovasculardisease,inurbanresidents,cancerhasbeentheleadingcauseofdeath.Thenumberofnewlydiagnosedcasesofcancereachyear2millionpeople,morethan1million600thousanddeaths,accountingfor18.63%ofthecountry'stotalaverageannualdeathtoll.Atpresent,theincidenceofcancerisstillasignificantupwardtrend,sotheanti-cancerdrughasahugemarket.A

Information

Text / Chai Yan
    Cancer is a malignant disease which is seriously harmful to human health. Every year around 7 million people in the world die from cancer. In our country, the tumor is only the high incidence of cardiovascular disease, in urban residents, cancer has been the leading cause of death. The number of newly diagnosed cases of cancer each year 2 million people, more than 1 million 600 thousand deaths, accounting for 18.63% of the country's total average annual death toll. At present, the incidence of cancer is still a significant upward trend, so the anti-cancer drug has a huge market.
    At present, the clinical commonly used antitumor drug is mainly cytotoxic drugs, this class of anticancer contraceptives is difficult to avoid the poor selectivity, strong side effects, easy to produce the resistance problem. The monoclonal antibody known as "biological missile" is considered to be the most promising biological drug for the cure of cancer in this century. Compared with conventional chemotherapy and monoclonal antibodies for tumor cell specific antigen selectively kill tumor cells. In a certain extent avoids to normal tissue destruction, especially to overcome tumor resistance and eliminate tumor residual tumor, metastasis have good application prospects.
    Baitai developed teshin health (nimotuzumab) in April 2005 received the State Food and Drug Administration issued a national new drug certificate, listed in March 2008, is China's first approved for humanized monoclonal antibody in the treatment of malignant tumor and the first have independent intellectual property rights of the humanized antibody therapeutics. It is a humanized monoclonal antibody against human epidermal growth factor receptor (EGFR) development, due to the adoption of advanced "CDR grafting technology, source of the person is as high as 95%, greatly reduce the immunogenicity of the antibody. Clinically proven Xintai students can be used for treatment of EGFR over expression in a variety of solid tumors, including head and neck tumor, brain, nerve glioma, nasopharyngeal carcinoma, non small cell lung cancer, esophageal cancer, gastric cancer, breast cancer, cervical cancer, colon cancer, pancreatic cancer, etc., can significantly improve the patient cure rate and survival rate, and side effects of mild, has high clinical application value and market potential is huge.

搜索

Biotech pharmaceutical co., Ltd

Address:NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd  京ICP备05019954号 互联网药品信息编号:(京)非经营性2016-0046    www.300.cn